- Oops!Something went wrong.Please try again later.
Bonus BioGroup (TASE: BONS), a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, has discovered that its COVID drug, MesenCure, can also reduce inflammatory overreaction seen in cancer patients treated with immunotherapy.
HAIFA, Israel, April 28, 2022 /PRNewswire/ -- Haifa-based Biotech company, Bonus BioGroup (TASE: BONS), has recently completed a preclinical trial demonstrating the efficacy of its drug MesenCure (developed for the treatment of severe COVID patients) in reducing life-threatening inflammatory overreaction, seen in patients with cytokine release syndrome (CRS).
This kind of inflammatory overreaction develops in up to 78% of cancer patients treated with biological immunotherapies that galvanize the immune system to fight cancer, and in patients transplanted with blood-forming stem cells. According to recent studies, up to 27% of cancer patients, who suffer from this condition, following such biological treatments, may develop a multi-system failure that could endanger their lives.
In a trial conducted by Bonus BioGroup at The Jackson Laboratory in California, one of the world's most respected research institutes, it was found that MesenCure significantly reduced the inflammatory overreaction that developed following biological cancer treatment, with complete response, demonstrating its potential to prevent life-threatening conditions in patients.
Experts estimate that by 2027, in the United States alone, more than 18,000 patients will suffer from an inflammatory overreaction following biological treatments for cancer and could subsequently develop a life-threatening condition.
Dr. Shai Meretzki, CEO of Bonus BioGroup, "The fact that MesenCure may also help oncological patients is an important milestone in our journey to realize Bonus BioGroup's vision to become a world leader in cellular therapy. This is a major step to position Bonus BioGroup as an essential player in the field of Oncology, in addition to regenerative medicine and tissue engineering."
Bonus BioGroup is also continuing its clinical development of the drug MesenCure to treat severe COVID patients towards launching a Phase III clinical trial in leading U.S. hospitals, as the virus will be living with us for a long time. With new strains discovered almost weekly, experts estimate that millions more severe COVID patients are expected every year worldwide.
About Bonus BioGroup and MesenCure therapy
Since its inception, Bonus BioGroup has been involved in cell therapy and tissue engineering to achieve bone tissue regeneration and reconstruction. The main building block utilized to produce the viable bone graft is mesenchymal cells extracted from the patient's adipose tissue. With the outbreak of the global Coronavirus epidemic, the company began experimenting with the very same mesenchymal cells, isolated from adipose tissue of healthy donors, and their activation to enhance their ability to reduce inflammatory processes, including respiratory infections and others.
These efforts led to the development of the cell therapy MesenCure.
SOURCE Bonus BioGroup